|
1
|
DiPiro JT: Pharmacotherapy: A
pathophysiologic approach. McGraw-Hill Medical. (New York).
2016.
|
|
2
|
Tasian SK, Pollard JA and Aplenc R:
Molecular therapeutic approaches for pediatric acute myeloid
leukemia. Front Oncol. 4:552014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shurin MR, Esche C and Lotze MT: FLT3:
Receptor and ligand. Biology and potential clinical application.
Cytokine Growth Factor Rev. 9:37–48. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakao M, Yokota S, Iwai T, Kaneko H,
Horiike S, Kashima K, Sonoda Y, Fujimoto T and Misawa S: Internal
tandem duplication of the flt3 gene found in acute myeloid
leukemia. Leukemia. 10:1911–1918. 1996.PubMed/NCBI
|
|
5
|
Kiyoi H, Towatari M, Yokota S, Hamaguchi
M, Ohno R, Saito H and Naoe T: Internal tandem duplication of the
FLT3 gene is a novel modality of elongation mutation which causes
constitutive activation of the product. Leukemia. 12:1333–1337.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R,
Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C,
et al: Activating mutation of D835 within the activation loop of
FLT3 in human hematologic malignancies. Blood. 97:2434–2439. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hayakawa F, Towatari M, Kiyoi H, Tanimoto
M, Kitamura T, Saito H and Naoe T: Tandem-duplicated Flt3
constitutively activates STAT5 and MAP kinase and introduces
autonomous cell growth in IL-3-dependent cell lines. Oncogene.
19:624–631. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schnittger S, Schoch C, Dugas M, Kern W,
Staib P, Wuchter C, Loffler H, Sauerland CM, Serve H, Buchner T, et
al: Analysis of FLT3 length mutations in 1003 patients with acute
myeloid leukemia: Correlation to cytogenetics, FAB subtype and
prognosis in the AMLCG study and usefulness as a marker for the
detection of minimal residual disease. Blood. 100:59–66. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thiede C, Steudel C, Mohr B, Schaich M,
Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M,
Neubauer A, et al: Analysis of FLT3-activating mutations in 979
patients with acute myelogenous leukemia: Association with FAB
subtypes and identification of subgroups with poor prognosis.
Blood. 99:4326–4335. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kiyoi H: Flt3 Inhibitors: Recent advances
and problems for clinical application. Nagoya J Med Sci. 77:7–17.
2015.PubMed/NCBI
|
|
11
|
Galanis A, Ma H, Rajkhowa T, Ramachandran
A, Small D, Cortes J and Levis M: Crenolanib is a potent inhibitor
of FLT3 with activity against resistance-conferring point mutants.
Blood. 123:94–100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
El Fakih R, Rasheed W, Hawsawi Y,
Alsermani M and Hassanein M: Targeting FLT3 mutations in acute
myeloid leukemia. Cells. 7(pii): E42018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Choi SJ, Moon MJ, Lee SD, Choi SU, Han SY
and Kim YC: Indirubin derivatives as potent FLT3 inhibitors with
anti-proliferative activity of acute myeloid leukemic cells. Bioorg
Med Chem Lett. 20:2033–2037. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee HJ, Lee J, Jeong P, Choi J, Baek J,
Ahn SJ, Moon Y, Heo JD, Choi YH, Chin YW, et al: Discovery of a
FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid
leukemia. Oncotarget. 9:924–936. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee J, Kang JS, Choi BY and Keum YS:
Sensitization of 5-fluorouracil-resistant SNUC5 colon cancer cells
to apoptosis by α-Mangostin. Biomol Ther (Seoul). 24:604–609. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiao Z, Hao Y, Liu B and Qian L: Indirubin
and meisoindigo in the treatment of chronic myelogenous leukemia in
China. Leuk Lymphoma. 43:1763–1768. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eisenbrand G, Hippe F, Jakobs S and
Muehlbeyer S: Molecular mechanisms of indirubin and its
derivatives: Novel anticancer molecules with their origin in
traditional Chinese phytomedicine. J Cancer Res Clin Oncol.
130:627–635. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gan WJ, Yang T, Wen S, Liu Y, Tan Z, Deng
C, Wu J and Liu M: Studies on the mechanism of indirubin action in
the treatment of chronic myelocytic leukemia (CML). II.
5′-Nucleotidase in the peripheral white blood cells of CML. Chin
Acad Med Sci Beijing. 6:611–613. 1985.
|
|
19
|
Zhang L, Wu GY, Qiu CC and Gao BH: Effect
of indirubin on DNA synthesis in vitro. Zhongguo Yi Xue Ke Xue Yuan
Xue Bao. 7:112–116. 1985.(In Chinese). PubMed/NCBI
|
|
20
|
Wu GY and Fang FD: Studies on the
mechanism of indirubin action in the treatment of chronic
granulocytic leukemia. II. Effects of indirubin on nucleic acid and
protein synthesis in animal transplantable tumor cells and normal
proliferating cells in vitro (author's transl)]. Zhongguo Yi Xue Ke
Xue Yuan Xue Bao. 2:83–87. 1980.(In Chinese). PubMed/NCBI
|
|
21
|
Hoessel R, Leclerc S, Endicott JA, Nobel
ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, et
al: Indirubin, the active constituent of a Chinese antileukaemia
medicine, inhibits cyclin-dependent kinases. Nat Cell Biol.
1:60–67. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leclerc S, Garnier M, Hoessel R, Marko D,
Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, et
al: Indirubins inhibit glycogen synthase kinase-3 beta and
CDK5/p25, two protein kinases involved in abnormal tau
phosphorylation in Alzheimer's disease. A property common to most
cyclin-dependent kinase inhibitors? J Biol Chem. 276:251–260.
2001.PubMed/NCBI
|
|
23
|
Li C, Go Y, Mao Z, Koyano K, Kai Y,
Kanehisa N, Zhu Q, Zhou Z and Wu S: The synthesis, antileukemic
activity and crystal structures of indirubin dervatives. Bull Chem
Soc Jpn. 69:1621–1627. 1996. View Article : Google Scholar
|
|
24
|
Moon MJ, Lee SK, Lee JW, Song WK, Kim SW,
Kim JI, Cho C, Choi SJ and Kim YC: Synthesis and structure-activity
relationships of novel indirubin derivatives as potent
anti-proliferative agents with CDK2 inhibitory activities. Bioorg
Med Chem. 14:237–246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Beauchard A, Ferandin Y, Frere S, Lozach
O, Blairvacq M, Meijer L, Thiery V and Besson T: Synthesis of novel
5-substituted indirubins as protein kinases inhibitors. Bioorg Med
Chem. 14:6434–6443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu L, Nam S, Tian Y, Yang F, Wu J, Wang
Y, Scuto A, Polychronopoulos P, Magiatis P, Skaltsounis L, et al:
6-Bromoindirubin-3′-oxime inhibits JAK/STAT3 signaling and induces
apoptosis of human melanoma cells. Cancer Res. 71:3972–3979. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Begum J, Skamnaki VT, Moffatt C, Bischler
N, Sarrou J, Skaltsounis AL, Leonidas DD, Oikonomakos NG and Hayes
JM: An evaluation of indirubin analogues as phosphorylase kinase
inhibitors. J Mol Graph Model. 61:231–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Myrianthopoulos V, Magiatis P, Ferandin Y,
Skaltsounis AL, Meijer L and Mikros E: An integrated computational
approach to the phenomenon of potent and selective inhibition of
Aurora kinases B and C by a series of 7-substituted indirubins. J
Med Chem. 50:4027–4037. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Myrianthopoulos V, Kritsanida M,
Gaboriaud-Kolar N, Magiatis P, Ferandin Y, Durieu E, Lozach O,
Cappel D, Soundararajan M, Filippakopoulos P, et al: Novel inverse
binding mode of indirubin derivatives yields improved selectivity
for DYRK kinases. ACS Med Chem Lett. 4:22–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
